DANIELLE WALDRON: Open Payments
NPI 1851724223 · LYNNWOOD, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 30 payments from 11 companies in 2025. Trend: 2023 $633 · 2024 $1,024 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $141 |
| ABBVIE INC. | 3 | $139 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 3 | $124 |
| Supernus Pharmaceuticals, Inc. | 5 | $109 |
| E.R. Squibb & Sons, L.L.C. | 1 | $81 |
| Bausch Health US, LLC | 4 | $72 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: CAPLYTA, VRAYLAR, Auvelity, Qelbree, COBENFY, ABILIFY ASIMTUFII, APLENZIN, REXULTI.
Industry payments across WA — which companies pay providers there.
